Procter & Gamble, the Consumer Defensive sector company, was revisited by a Wall Street analyst yesterday. Analyst Dara Mohsenian from Morgan Stanley maintained a Buy rating on the stock and has a $175.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dara Mohsenian has given his Buy rating due to a combination of factors that highlight Procter & Gamble’s strong performance and future potential. The company delivered impressive first-quarter earnings that surpassed consensus expectations, demonstrating resilience in a challenging industry environment. Despite a softer outlook for the second quarter, Procter & Gamble’s full-year guidance remains intact, supported by lower commodity and tariff costs, which are expected to provide some relief.
Procter & Gamble’s robust productivity program, which includes significant job cuts, is anticipated to yield substantial benefits in the latter half of the fiscal year. This positions the company favorably compared to its peers, who are facing negative earnings revisions. Furthermore, Procter & Gamble’s visibility and expected sequential improvement in organic sales growth enhance its attractiveness as an investment, making it a solid choice on a relative basis in the household and personal care sector.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $168.00 price target.